<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml">
   <article xmlns="" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
      <head>
         <style type="text/css"> 		 
            	    table {background : #ffffdd;}
            		 	tr {background : #ddddff; padding : 1px;}
            			
         </style>
         <span class="citation_publisher">Hindawi Publishing Corporation</span>
         <h2 class="citation-title">Gastric Mucinous Cancer Histology: Clinicopathological Characteristics and Prognostic
            Value
         </h2>
         <span class="doi">10.1155/2016/8947505</span>
         <div class="contrib-group">contrib: 
            	  CONT
            	  
            <span class="citation_author">Chen Jian-Hui</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Cai Shi-Rong</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Wu Hui</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Xu Jian-bo</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Wu Kai-Ming</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Chen Si-le</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Yu-Long He</span>
            <span class="citation_author_institution_ref">1</span>
         </div>
         <span class="email">[ylh@medmail.com.cn]</span>
         <span class="conflict">[]</span>
         <span class="contribs">[]</span>
         <span class="citation_pubdate">[2015-12-29]</span>
         <span class="citation_copyright">[Copyright 2016: ]</span>
         <span class="citation_licence">[Licence This is an open access article distributed under the Creative Commons Attribution
            License, which permits unrestricted use, distribution, and reproduction in any medium,
            provided the original work is properly cited.]
         </span>
         <span class="citation_funding">[]</span>
         <span class="citation_pagecount">[]</span>
         <span class="citation_data">[]</span>
      </head>
      <div id="abstract" tag="abstract">
         <h2>Abstract</h2>
         <p>MC tended toward worse tumor biological behavior and long-term survival outcome compared
            to WMDC. Moreover, MC also showed worse clinicopathological features and survival
            outcome in some selected patients. For these reasons, MC should be deemed as a special
            histological type of gastric cancer with worse clinicopathological features and survival
            outcome.
         </p>
      </div>
      <div tagxxx="sec">
         <title>1. Introduction</title>
         <p>The adenocarcinoma from several organs can secret the mucinous-like substance, including
            the gastrointestinal track. The incidence of colorectal mucinous cancer (MC) is higher
            than that of gastric MC. According to the literature, the colorectal MC accounts for
            7.0% to 14.8% [
            <span ref-type="bibr" rid="B1">
               <sup>
                  <a href="#B1">1</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B3">
               <sup>
                  <a href="#B3">3</a>
               </sup>
            </span>] in all histological types of colorectal cancer, and it indicates larger tumor size,
            deeper invasion, and poorer survival outcome. Moreover, the MC is a rare histological
            type in gastric carcinoma, occupying from 3.3% to 7.1% of total gastric cancer patients
            [
            <span ref-type="bibr" rid="B4">
               <sup>
                  <a href="#B4">4</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>]. The pathological manifestation of this histological type is defined by the World
            Health Organization (WHO) as the mucus aggregates in the tumor stroma and forms mucinous
            pools, occupying the majority of the whole view in the microscope (more than 50%).
            The mucinous pool locating intracellularly and small amount of extracellular mucus
            aggregation are the exclusive criteria of MC.
         </p>
         <p>The clinical characteristics and prognosis of MC are still controversial because of
            the small sample size of MC cases. Some believed that the MC patients had worse clinical
            parameters and survival prognosis [
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>]; some [
            <span ref-type="bibr" rid="B8">
               <sup>
                  <a href="#B8">8</a>
               </sup>
            </span>] insisted that there were no distribution differences of clinical characteristics
            and survival difference between MC and nonmucinous cancer (NMC) for gastric cancer.
            It is worth noting that in these articles the comparison object of MC was the NMC
            which included both well and moderately differentiated cancer (WMDC) and poor differentiated
            cancer (PDC) [
            <span ref-type="bibr" rid="B9">
               <sup>
                  <a href="#B9">9</a>
               </sup>
            </span>]. The different compositions of NMC may lead to the controversial results in the
            literature. Aiming at finding out the exactly clinical significance and survival outcome
            of this rare histological type, we compared MC to WMDC and PDC, respectively.
         </p>
      </div>
      <div tagxxx="sec">
         <title>2. Materials and Methods</title>
         <p>From June 1995 to December 2006, there were consecutive 996 primary gastric adenocarcinoma
            patients who had undergone palliative or curative gastrectomy with completed data
            at the Department of Gastrointestinal and Pancreatic Surgery, The First Affiliated
            Hospital of Sun Yat-Sen University. The uncommon histological types were excluded,
            such as adenosquamous carcinomas, hepatoid carcinomas, gastric carcinoma with lymphoid
            stroma, and gastric carcinoma with gastrointestinal stromal tumors.
         </p>
         <p>We adopted the retrospective analysis. The clinical parameters were investigated,
            such as age, gender, tumor diameter, tumor location, Borrmann types, tumor invasion,
            lymph node metastasis, distant metastasis, peritoneal dissemination, hepatic metastasis,
            TNM stage, and operative curability. The operation was deemed as curative when the
            tumor specimen and regional lymph nodes were completely resected and the resection
            margin was negative in histological examination. The distant metastasis included peritoneal
            dissemination, hepatic metastasis, and nonregional lymph node metastasis. The pathological
            findings were carried out by two special pathologists independently and further confirmed
            by an experienced pathological expert to make a final diagnosis. The classifications
            of tumor invasion, lymph node metastasis, and distant metastasis were according to
            the 7th edition of UICC/AJCC TNM stage. The definitions of histological type for gastric
            cancer followed the criteria of the WHO classification and were revealed previously.
            In our study, there were 68 gastric MC patients (accounting for 6.8%), 329 WMDC cases
            (accounting for 33.0%), and 599 PDC ones (accounting for 60.2%).
         </p>
         <p>All the patients received follow-up programs that followed the concurrent NCCN/AJCC
            guideline, including body examination, laboratory examination, check X-ray, and abdominal
            CT scan/abdominal ultrasound and gastroscopy. The follow-up protocol was every 3 months
            for the postoperative two years, every 4 months for the next 1 year, every 6 months
            for the next 2 years, and after 5 years every 12 months until death. The latest follow-up
            date was December 2013. The follow-up period for all the patients was more than 5
            years. 4.4% (44/996) patients were lost during follow-up survey.
         </p>
         <p>Chi-square test was used to compare the distribution differences of individual variables
            between groups. Survival curve was conducted using the Kaplan-Meier method and the
            survival differences were compared using the log-rank test. Cox proportional hazards
            regression model and the forward: LR procedure were used for univariate and multivariate
            analysis. Only the statistically significant prognostic factors in the univariate
            analysis were further used for multivariate analysis. The accepted level of significance
            was 
            <i>P</i> &lt; 0.05. The statistical package used in this study was the Statistical Package for
            Social Sciences (SPSS 18.0, Chicago, IL, USA).
         </p>
      </div>
      <div tagxxx="sec">
         <title>3. Results</title>
         <div tagxxx="sec">
            <h3>3.1. Clinicopathological Parameters Comparison between MC and WGMDC and PDC Patients</h3>
            <p>The clinicopathological features of MGC, WMDC, and PDC patients were compared (Tables
               
               <span ref-type="table" rid="tab1">
                  <a href="#tab1">1</a>
               </span> and 
               <span ref-type="table" rid="tab2">
                  <a href="#tab2">2</a>
               </span>). There was no significant difference of the average age between MC groups and WMDC
               groups (59.2 years old and 60.8 years old, resp.) and no significant difference in
               the distribution of the elder proportion was found too. Moreover, the average age
               of MC patients was higher than that of PDC patients (54.1 years old) and MC group
               had statistically larger proportion (50.0%) of the elder cases than the PDC ones (36.2%).
               Moreover, there were no significant differences in the distribution of the gender,
               tumor location, and Borrmann type among MC group, WMDC group, and PDC one. The mean
               tumor diameter of MC, WMDC, and PDC was 6.81 cm, 5.18 cm, and 6.31 cm, respectively,
               and we found more MC patients with larger tumor size (&gt;5 cm) than WMDC cases. From
               
               <span ref-type="table" rid="tab1">
                  <a href="#tab1">Table 1</a>
               </span> we found a significantly worse clinicopathological features of tumor invasion, lymph
               node involvement, peritoneal seeding, TNM stage in MC patients than in WMDC cases.
               Moreover, MC patients also exhibited a worse tumor biological behavior of tumor invasion
               and peritoneal dissemination compared to PDC patients and no distributions of lymph
               node involvement, TNM stage, and liver metastasis were found between MC group and
               PDC group. The radical resection rate of different histological types for gastric
               cancer in the descending sequence is as follows: WMDC (77.8%), PDC (70.3%), and MC
               (63.2%). A statistical difference of radical resection rate between MC patients and
               WMDC ones was observed.
            </p>
         </div>
         <div tagxxx="sec">
            <h3>3.2. Survival Analysis</h3>
            <div tagxxx="sec">
               <h3>3.2.1. Survival Comparison between Gastric MC and WMDC Patients</h3>
               <p>The median survival time (MST) of MC and WMDC patients was 26.7 months and 67.4 months,
                  respectively. Using Kaplan-Meier analysis, there were statistical differences between
                  MC patients and WMDC patients (
                  <i>χ</i>
                  <sup>2</sup> = 12.61, 
                  <i>P</i> = 0.004). However, there was no survival difference between MC and WMDC patients
                  with early stage, and the patients with advanced MC had worse prognostic outcome than
                  the ones with advanced WMDC. The data was shown in 
                  <span ref-type="table" rid="tab3">
                     <a href="#tab3">Table 3</a>
                  </span> and 
                  <span ref-type="fig" rid="fig1">Figure 1</span>.
               </p>
            </div>
            <div tagxxx="sec">
               <h3>3.2.2. Survival Comparison between MC and PDC Patients</h3>
               <p>
                  <i>(1) Overall Survival Comparison</i>. We found that the long-term survival outcome of PDC patients was better than the
                  one of MC cases, although the survival difference had no statistical significance
                  (
                  <i>χ</i>
                  <sup>2</sup> = 2.020, 
                  <i>P</i> = 0.155). Moreover, no survival differences were found between PDC and MC patients
                  no matter in the early stage or advanced stage. The data was shown in 
                  <span ref-type="table" rid="tab4">
                     <a href="#tab4">Table 4</a>
                  </span> and 
                  <span ref-type="fig" rid="fig2">Figure 2</span>.
               </p>
               <p>
                  <i>(2) Subgroup Survival Comparison</i>. We further compared the survival differences between MC patients and PDC ones by
                  stratified analysis. The results in 
                  <span ref-type="fig" rid="fig3">Figure 3</span> indicated that only when patients are with age ≤ 60 years, tumor diameter ≤ 5 cm,
                  and Borrmann type III, did MC group show a worse survival outcome than PDC groups
                  (
                  <span ref-type="table" rid="tab5">
                     <a href="#tab5">Table 5</a>
                  </span>). Subgroup analysis for the parameters of gender, tumor location, depth of invasion,
                  lymph node metastasis, peritoneal metastasis, liver metastasis, TNM stage, and radical
                  resection did not affect the survival outcome between two groups.
               </p>
            </div>
         </div>
         <div tagxxx="sec">
            <h3>3.3. Cox Regression Analysis</h3>
            <p>The histological analysis in our study was divided into three parts: WMDC group, MC
               group, and PDC group. As shown in 
               <span ref-type="table" rid="tab6">
                  <a href="#tab6">Table 6</a>
               </span>, univariate regression analysis shows that the elder age, Borrmann type, histological
               types, tumor diameter, depth of invasion, lymph node metastasis, distant metastasis,
               TNM stage, radical resection, and chemotherapy affected the overall survival prognosis
               in our study. Only the significantly statistical prognostic factors in the univariate
               analysis were used for further multivariate analysis. And the multivariate Cox regression
               analysis indicated that age, tumor diameter, lymph node metastasis, TNM classification,
               adjuvant chemotherapy, and radical dissection were the independent prognostic factors.
               However, the histological factor was not the independent prognostic factor for gastric
               cancer in our study.
            </p>
         </div>
      </div>
      <div tagxxx="sec">
         <title>4. Discussion</title>
         <p>There were many classifications of histological types for gastric cancer, such as
            Lauren classification [
            <span ref-type="bibr" rid="B10">
               <sup>
                  <a href="#B10">10</a>
               </sup>
            </span>], Ming classification [
            <span ref-type="bibr" rid="B11">
               <sup>
                  <a href="#B11">11</a>
               </sup>
            </span>], and WHO classification. Nowadays, WHO classification is widely used worldwide.
            The WHO histological classification for gastric cancer can divide into well differentiation
            types (well differentiated and moderately differentiated) and poor differentiation
            types (poorly differentiated and undifferentiated) [
            <span ref-type="bibr" rid="B12">
               <sup>
                  <a href="#B12">12</a>
               </sup>
            </span>]. The well differentiation types included papillary and well differentiated and moderately
            differentiated cancer, and the poor differentiation types included poor differentiated
            and mucinous cancer and signet ring cell carcinoma and undifferentiated carcinoma.
            MC, a rare kind of poor differentiation histological type, had abundant mucus in the
            tumor issue, with nest-like or mass shape generated by the tumor cell accumulating
            in the cancer nests. However, controversy still existed on the clinicopathological
            characteristics and prognostic factors.
         </p>
         <p>In our study, we found that MC had a tendency to have larger tumor size, deeper gastric
            wall invasion, more frequent lymph node involvement, more advanced tumor stage, more
            peritoneal dissemination, and less curative rate than WMDC. Similar findings were
            reported in the previous studies [
            <span ref-type="bibr" rid="B5">
               <sup>
                  <a href="#B5">5</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>] when MGC was compared to NMC. However, there were little studies to compare MC to
            PDC. Some authors [
            <span ref-type="bibr" rid="B4">
               <sup>
                  <a href="#B4">4</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B13">
               <sup>
                  <a href="#B13">13</a>
               </sup>
            </span>] just compared the clinicopathological characteristics of MGC to a small part of
            PDC, gastric signet ring cell cancer (GSRCC). In our study, we found out that although
            the clinicopathological features of MC were worse than those of PDC, the differences
            in the distribution of the clinicopathological features between MGC and PDC were smaller.
            There were distribution differences only in the cases with senile ones, gastric wall
            invasion, and peritoneal dissemination. Hence the opposite conclusions made by Kawamura
            et al. [
            <span ref-type="bibr" rid="B14">
               <sup>
                  <a href="#B14">14</a>
               </sup>
            </span>] and Adachi et al. [
            <span ref-type="bibr" rid="B8">
               <sup>
                  <a href="#B8">8</a>
               </sup>
            </span>] may be due to the different proportion of PDC in the NMC patients (Kawamura: 53.2%
            and Adachi: 41%).
         </p>
         <p>Up to the present, most of the authors insisted that MC represented a worse tumor
            biological behaviors and had deeper invasion, more lymph node involvement, more advanced
            tumor stage, and low radical resection rate, which led to a poorer survival outcome
            than NMC [
            <span ref-type="bibr" rid="B5">
               <sup>
                  <a href="#B5">5</a>
               </sup>
            </span>]. Nevertheless, some revealed that there was no survival difference between MC and
            NMC for the patients with the same stage [
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B15">
               <sup>
                  <a href="#B15">15</a>
               </sup>
            </span>]. In order to explore the exact survival outcome of MC, our study distinguished the
            survival differences between MC, WMDC, and PDC. The survival times in the descending
            order were listed as follows: WMDC (50.9%), PDC (38.4%), and MC (29.4%). A significantly
            statistical difference was found between WMDC and MC and there was no survival difference
            between MC and PDC. Interestingly, the patients with age ≤ 60 years, tumor diameter
            ≤ 5 cm, and Borrmann type III in the MC group showed a worse overall survival outcome
            than those in the PDC group. Our result may give help to explain and distinguish survival
            results. We found that a larger proportion of PDC in the NMC may lead to a smaller
            survival difference. Kawamura et al. [
            <span ref-type="bibr" rid="B14">
               <sup>
                  <a href="#B14">14</a>
               </sup>
            </span>] showed a worse survival outcome of MC than of NMC and PDC accounted for 45.1% in
            NMC, while Park held an opposite view and PDC accounted for 50.1% in NMC. This comparison
            showed that, with the smaller proportion of PDC, MC showed a poorer outcome compared
            with NMC.
         </p>
         <p>Similar to most of the authors [
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B16">
               <sup>
                  <a href="#B16">16</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B17">
               <sup>
                  <a href="#B17">17</a>
               </sup>
            </span>], the mucinous histological type itself was not an independent prognostic factor
            in Cox proportional hazard model in our study, but age, tumor diameter, depth of invasion,
            lymph node metastasis, TNM stage, adjuvant chemotherapy, and radical resection were
            independent prognostic factors in our study. It was possible that most of the gastric
            patients in our study were detected in the advanced stage at diagnosis and the mucinous
            histological type had little prognosis significance.
         </p>
         <p>In conclusion, MC tended toward worse tumor biological behavior and long-term survival
            outcome compared to WMDC. Moreover, MC also showed worse clinicopathological features
            (more senile people, advanced tumor invasion, and frequent peritoneal metastasis).
            No survival difference was found between MC and PDC. Only MC patients with age ≤ 60
            years, tumor diameter ≤ 5 cm, and Borrmann type III, showed a worse survival outcome
            than did PDC groups. For these reasons, MC should be deemed as a special histological
            type of gastric cancer.
         </p>
      </div>
      <back>
         <div tagxxx="ack">
            <title>Acknowledgments</title>
            <p>This study was supported by research grants from Financial Disclosure information
               and from the National Nature Science Foundation of China (no. 8137234, no. 81272637,
               and no. 81372341) and Guangdong Province Natural Science Fund of China (no. 2014A030310111).
            </p>
         </div>
         <div tagxxx="sec">
            <title>Conflict of Interests</title>
            <p>The authors declare they have no conflict of interests which are relevant to the paper.</p>
         </div>
         <div tagxxx="sec">
            <title>Authors' Contribution</title>
            <p>Dr. Cai Shi-Rong and Dr. Chen Jian-Hui contributed equally to this study, including
               study concept and design, analysis and interpretation of data, drafting of the paper,
               and critical revision of the paper for important intellectual content. Dr. Wu Hui,
               Xu Jian-bo, Chen Si-le, and Wu Kai-Ming participated in the acquisition of data and
               statistical analysis. Dr. Yu-Long He supervised the whole study and monitored the
               standard surgical operations. All the authors took part in the surgical operations
               for gastric cancer. Jian-Hui Chen and Shi-Rong Cai contributed equally to this work.
            </p>
         </div>
         <div tag="ref-list">
            <ul>
               <li tag="ref">
                  <a name="B1"></a>
                  <label>1</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Song</span>
                           <span tagx="given-names">W.</span>
                        </name>
                        <name>
                           <span tagx="surname">Wu</span>
                           <span tagx="given-names">S.-J.</span>
                        </name>
                        <name>
                           <span tagx="surname">He</span>
                           <span tagx="given-names">Y.-L.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring
                        cell or non-mucinous adenocarcinoma: experience at an institution in southern China
                     </span>
                     <span tagx="source">
                        <i>Chinese Medical Journal</i>
                     </span>
                     <span tagx="year">2009</span>
                     <span tagx="volume">122</span>
                     <div tagxxx="issue">13</div>
                     <span tagx="fpage">1486</span>
                     <span tagx="lpage">1491</span>
                     <span class="pub-id'">[10.3760/cma.j.issn.0366-6999.2009.13.002]</span>
                     <span class="pub-id'">[2-s2.0-70349558077]</span>
                     <span class="pub-id'">[19719934]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B2"></a>
                  <label>2</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Dakubo</span>
                           <span tagx="given-names">J. C. B.</span>
                        </name>
                        <name>
                           <span tagx="surname">Naaeder</span>
                           <span tagx="given-names">S. S. B.</span>
                        </name>
                        <name>
                           <span tagx="surname">Gyasi</span>
                           <span tagx="given-names">R. K.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Clinicopathological aspects of adenocarcinoma of the large bowel in a low incidence
                        population
                     </span>
                     <span tagx="source">
                        <i>Journal of Surgical Oncology</i>
                     </span>
                     <span tagx="year">2014</span>
                     <span tagx="volume">109</span>
                     <div tagxxx="issue">3</div>
                     <span tagx="fpage">245</span>
                     <span tagx="lpage">249</span>
                     <span class="pub-id'">[10.1002/jso.23489]</span>
                     <span class="pub-id'">[2-s2.0-84893662162]</span>
                     <span class="pub-id'">[24249202]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B3"></a>
                  <label>3</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Nitsche</span>
                           <span tagx="given-names">U.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zimmermann</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Späth</span>
                           <span tagx="given-names">C.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas
                        in tumor biology and prognosis
                     </span>
                     <span tagx="source">
                        <i>Annals of Surgery</i>
                     </span>
                     <span tagx="year">2013</span>
                     <span tagx="volume">258</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">775</span>
                     <span tagx="lpage">783</span>
                     <span class="pub-id'">[10.1097/SLA.0b013e3182a69f7e]</span>
                     <span class="pub-id'">[2-s2.0-84886090772]</span>
                     <span class="pub-id'">[23989057]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B4"></a>
                  <label>4</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Jiang</span>
                           <span tagx="given-names">H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zhang</span>
                           <span tagx="given-names">H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Tian</span>
                           <span tagx="given-names">L.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zhang</span>
                           <span tagx="given-names">X.</span>
                        </name>
                        <name>
                           <span tagx="surname">Xue</span>
                           <span tagx="given-names">Y.</span>
                        </name>
                     </span>
                     <span tagx="article-title">The difference in clinic-pathological features between signet ring cell carcinoma
                        and gastric mucinous adenocarcinoma
                     </span>
                     <span tagx="source">
                        <i>Tumor Biology</i>
                     </span>
                     <span tagx="year">2013</span>
                     <span tagx="volume">34</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">2625</span>
                     <span tagx="lpage">2631</span>
                     <span class="pub-id'">[10.1007/s13277-013-0812-1]</span>
                     <span class="pub-id'">[2-s2.0-84885428084]</span>
                     <span class="pub-id'">[23636798]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B5"></a>
                  <label>5</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Yin</span>
                           <span tagx="given-names">C.</span>
                        </name>
                        <name>
                           <span tagx="surname">Li</span>
                           <span tagx="given-names">D.</span>
                        </name>
                        <name>
                           <span tagx="surname">Sun</span>
                           <span tagx="given-names">Z.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Clinicopathologic features and prognosis analysis of mucinous gastric carcinoma</span>
                     <span tagx="source">
                        <i>Medical Oncology</i>
                     </span>
                     <span tagx="year">2012</span>
                     <span tagx="volume">29</span>
                     <div tagxxx="issue">2</div>
                     <span tagx="fpage">864</span>
                     <span tagx="lpage">870</span>
                     <span class="pub-id'">[10.1007/s12032-011-9825-z]</span>
                     <span class="pub-id'">[2-s2.0-84866281844]</span>
                     <span class="pub-id'">[21298368]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B6"></a>
                  <label>6</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Zhang</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zhu</span>
                           <span tagx="given-names">G.-Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zhang</span>
                           <span tagx="given-names">H.-F.</span>
                        </name>
                        <name>
                           <span tagx="surname">Gao</span>
                           <span tagx="given-names">H.-Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Han</span>
                           <span tagx="given-names">X.-F.</span>
                        </name>
                        <name>
                           <span tagx="surname">Xue</span>
                           <span tagx="given-names">Y.-W.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Clinicopathologic characteristics and prognosis of mucinous gastric carcinoma</span>
                     <span tagx="source">
                        <i>Journal of Surgical Oncology</i>
                     </span>
                     <span tagx="year">2010</span>
                     <span tagx="volume">102</span>
                     <div tagxxx="issue">1</div>
                     <span tagx="fpage">64</span>
                     <span tagx="lpage">67</span>
                     <span class="pub-id'">[10.1002/jso.21533]</span>
                     <span class="pub-id'">[2-s2.0-77954137207]</span>
                     <span class="pub-id'">[20578080]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B7"></a>
                  <label>7</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Choi</span>
                           <span tagx="given-names">M.-G.</span>
                        </name>
                        <name>
                           <span tagx="surname">Sung</span>
                           <span tagx="given-names">C. O.</span>
                        </name>
                        <name>
                           <span tagx="surname">Noh</span>
                           <span tagx="given-names">J. H.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Mucinous gastric cancer presents with more advanced tumor stage and weaker 
                        <i>β</i>-catenin expression than nonmucinous cancer
                     </span>
                     <span tagx="source">
                        <i>Annals of Surgical Oncology</i>
                     </span>
                     <span tagx="year">2010</span>
                     <span tagx="volume">17</span>
                     <div tagxxx="issue">11</div>
                     <span tagx="fpage">3053</span>
                     <span tagx="lpage">3058</span>
                     <span class="pub-id'">[10.1245/s10434-010-1184-z]</span>
                     <span class="pub-id'">[2-s2.0-78049463268]</span>
                     <span class="pub-id'">[20645013]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B8"></a>
                  <label>8</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Adachi</span>
                           <span tagx="given-names">Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Yasuda</span>
                           <span tagx="given-names">K.</span>
                        </name>
                        <name>
                           <span tagx="surname">Inomata</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Shiraishi</span>
                           <span tagx="given-names">N.</span>
                        </name>
                        <name>
                           <span tagx="surname">Kitano</span>
                           <span tagx="given-names">S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Sugimachi</span>
                           <span tagx="given-names">K.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Clinicopathologic study of early-stage mucinous gastric carcinoma</span>
                     <span tagx="source">
                        <i>Cancer</i>
                     </span>
                     <span tagx="year">2001</span>
                     <span tagx="volume">91</span>
                     <div tagxxx="issue">4</div>
                     <span tagx="fpage">698</span>
                     <span tagx="lpage">703</span>
                     <span class="pub-id'">[10.1002/1097-0142(20010215)91:4&lt;698::AID-CNCR1054&gt;3.0.CO;2-O]</span>
                     <span class="pub-id'">[2-s2.0-0035864849]</span>
                     <span class="pub-id'">[11241236]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B9"></a>
                  <label>9</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Adachi</span>
                           <span tagx="given-names">Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Yasuda</span>
                           <span tagx="given-names">K.</span>
                        </name>
                        <name>
                           <span tagx="surname">Inomata</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Sato</span>
                           <span tagx="given-names">K.</span>
                        </name>
                        <name>
                           <span tagx="surname">Shiraishi</span>
                           <span tagx="given-names">N.</span>
                        </name>
                        <name>
                           <span tagx="surname">Kitano</span>
                           <span tagx="given-names">S.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type</span>
                     <span tagx="source">
                        <i>Cancer</i>
                     </span>
                     <span tagx="year">2000</span>
                     <span tagx="volume">89</span>
                     <div tagxxx="issue">7</div>
                     <span tagx="fpage">1418</span>
                     <span tagx="lpage">1424</span>
                     <span class="pub-id'">[10.1002/1097-0142(20001001)89:7&lt;1418::aid-cncr2&gt;3.0.co;2-a]</span>
                     <span class="pub-id'">[2-s2.0-0034307201]</span>
                     <span class="pub-id'">[11013353]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B10"></a>
                  <label>10</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Lauren</span>
                           <span tagx="given-names">P.</span>
                        </name>
                     </span>
                     <span tagx="article-title">The two histologic main types of gastric carcinoma: diffuse and so-called intestinal-type
                        carcinoma: an attempt at a histo-clinical classification
                     </span>
                     <span tagx="source">
                        <i>Acta Pathologica Microbiologica Scandinavica</i>
                     </span>
                     <span tagx="year">1965</span>
                     <span tagx="volume">64</span>
                     <span tagx="fpage">31</span>
                     <span tagx="lpage">49</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B11"></a>
                  <label>11</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Ming</span>
                           <span tagx="given-names">S. C.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Gastric carcinoma. A pathobiological classification</span>
                     <span tagx="source">
                        <i>Cancer</i>
                     </span>
                     <span tagx="year">1977</span>
                     <span tagx="volume">39</span>
                     <div tagxxx="issue">6</div>
                     <span tagx="fpage">2475</span>
                     <span tagx="lpage">2485</span>
                     <span class="pub-id'">[10.1002/1097-0142(197706)39:6x003C;2475::aid-cncr2820390626x0003e;3.0.co;2-l]</span>
                     <span class="pub-id'">[2-s2.0-0017385753]</span>
                     <span class="pub-id'">[872047]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B12"></a>
                  <label>12</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Lauwers</span>
                           <span tagx="given-names">G. Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Carneiro</span>
                           <span tagx="given-names">F.</span>
                        </name>
                        <name>
                           <span tagx="surname">Graham</span>
                           <span tagx="given-names">D. Y.</span>
                        </name>
                     </span>
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Bowman</span>
                           <span tagx="given-names">F. T.</span>
                        </name>
                        <name>
                           <span tagx="surname">Carneiro</span>
                           <span tagx="given-names">F.</span>
                        </name>
                        <name>
                           <span tagx="surname">Hruban</span>
                           <span tagx="given-names">R. H.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Gastric carcinoma</span>
                     <span tagx="source">
                        <i>Classification of Tumours of the Digestive System</i>
                     </span>
                     <span tagx="year">2010</span>
                     <span class="publisher-loc'">[Lyon, France]</span>
                     <span class="publisher-name'">[IARC]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B13"></a>
                  <label>13</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Bu</span>
                           <span tagx="given-names">Z.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zheng</span>
                           <span tagx="given-names">Z.</span>
                        </name>
                        <name>
                           <span tagx="surname">Li</span>
                           <span tagx="given-names">Z.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Clinicopathological and prognostic differences between mucinous gastric carcinoma
                        and signet-ring cell carcinoma
                     </span>
                     <span tagx="source">
                        <i>Chinese Journal of Cancer Research</i>
                     </span>
                     <span tagx="year">2013</span>
                     <span tagx="volume">25</span>
                     <div tagxxx="issue">1</div>
                     <span tagx="fpage">32</span>
                     <span tagx="lpage">38</span>
                     <span class="pub-id'">[10.3978/j.issn.1000-9604.2013.01.05]</span>
                     <span class="pub-id'">[2-s2.0-84883797641]</span>
                     <span class="pub-id'">[23372339]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B14"></a>
                  <label>14</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Kawamura</span>
                           <span tagx="given-names">H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Kondo</span>
                           <span tagx="given-names">Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Osawa</span>
                           <span tagx="given-names">S.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">A clinicopathologic study of mucinous adenocarcinoma of the stomach</span>
                     <span tagx="source">
                        <i>Gastric Cancer</i>
                     </span>
                     <span tagx="year">2001</span>
                     <span tagx="volume">4</span>
                     <div tagxxx="issue">2</div>
                     <span tagx="fpage">83</span>
                     <span tagx="lpage">86</span>
                     <span class="pub-id'">[10.1007/PL00011728]</span>
                     <span class="pub-id'">[2-s2.0-0034800090]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B15"></a>
                  <label>15</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Yasuda</span>
                           <span tagx="given-names">K.</span>
                        </name>
                        <name>
                           <span tagx="surname">Shiraishi</span>
                           <span tagx="given-names">N.</span>
                        </name>
                        <name>
                           <span tagx="surname">Inomata</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Shiroshita</span>
                           <span tagx="given-names">H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Ishikawa</span>
                           <span tagx="given-names">K.</span>
                        </name>
                        <name>
                           <span tagx="surname">Kitano</span>
                           <span tagx="given-names">S.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Clinicopathologic characteristics of early-stage mucinous gastric carcinoma</span>
                     <span tagx="source">
                        <i>Journal of Clinical Gastroenterology</i>
                     </span>
                     <span tagx="year">2004</span>
                     <span tagx="volume">38</span>
                     <div tagxxx="issue">6</div>
                     <span tagx="fpage">507</span>
                     <span tagx="lpage">511</span>
                     <span class="pub-id'">[10.1097/01.mcg.0000128991.59549.9a]</span>
                     <span class="pub-id'">[2-s2.0-3042660263]</span>
                     <span class="pub-id'">[15220686]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B16"></a>
                  <label>16</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Lee</span>
                           <span tagx="given-names">H. H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Song</span>
                           <span tagx="given-names">K. Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Park</span>
                           <span tagx="given-names">C. H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Jeon</span>
                           <span tagx="given-names">H. M.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Undifferentiated-type gastric adenocarcinoma: prognostic impact of three histological
                        types
                     </span>
                     <span tagx="source">
                        <i>World Journal of Surgical Oncology</i>
                     </span>
                     <span tagx="year">2012</span>
                     <span tagx="volume">10, article 254</span>
                     <span class="pub-id'">[10.1186/1477-7819-10-254]</span>
                     <span class="pub-id'">[2-s2.0-84869884125]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B17"></a>
                  <label>17</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Hidaka</span>
                           <span tagx="given-names">S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Tanaka</span>
                           <span tagx="given-names">K.</span>
                        </name>
                        <name>
                           <span tagx="surname">Takeshita</span>
                           <span tagx="given-names">H.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Clinicopathology and prognosis of mucinous gastric carcinoma</span>
                     <span tagx="source">
                        <i>Hepato-Gastroenterology</i>
                     </span>
                     <span tagx="year">2008</span>
                     <span tagx="volume">55</span>
                     <div tagxxx="issue">82-83</div>
                     <span tagx="fpage">791</span>
                     <span tagx="lpage">794</span>
                     <span class="pub-id'">[2-s2.0-44349110679]</span>
                     <span class="pub-id'">[18613456]</span>
                  </span>
               </li>
            </ul>
         </div>
      </back>
      <div tagxxx="floats-group">
         <fig>
            <label>Figure 1</label>
            <caption>
               <p>Survival comparison between MC and WMDC patients. (a) Total patients. (b) Patients
                  in the early stage. (c) Patients in the advanced stage.
               </p>
            </caption>
            <graphic></graphic>
         </fig>
         <fig>
            <label>Figure 2</label>
            <caption>
               <p>Survival comparison between MC and PDC patients. (a) Total patients. (b) Patients
                  in the early stage. (c) Patients in the advanced stage.
               </p>
            </caption>
            <graphic></graphic>
         </fig>
         <fig>
            <label>Figure 3</label>
            <caption>
               <p>Subgroup survival comparison between MC and PDC patients. (a) Patients with ages ≦
                  60 years (
                  <i>P</i> = 0.046). (b) Patients with tumor diameter ≦ 5 cm (
                  <i>P</i> = 0.029). (c) Patients with Borrmann type III (
                  <i>P</i> = 0.023).
               </p>
            </caption>
            <graphic></graphic>
         </fig>
         <div id="tab1">
            <label>Table 1</label>
            <caption>
               <p>Comparison of clinicopathological features between MC and WMDC patients for gastric
                  cancer.
               </p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th> </th>
                     <th>MC (68 cases)</th>
                     <th>WMDC (329 cases)</th>
                     <th>
                        <i>χ</i>
                        <sup>2</sup> value
                     </th>
                     <th>
                        <i>P</i> value
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Age </td>
                     <td> </td>
                     <td> </td>
                     <td>0.571</td>
                     <td>0.450</td>
                  </tr>
                  <tr>
                     <td> ≤60 years</td>
                     <td>34 (50.0%)</td>
                     <td>148 (45.0%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> &gt;60 years</td>
                     <td>34 (50.0%)</td>
                     <td>181 (55.0%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Gender </td>
                     <td> </td>
                     <td> </td>
                     <td>3.513</td>
                     <td>0.061</td>
                  </tr>
                  <tr>
                     <td> Male </td>
                     <td>44 (64.7%)</td>
                     <td>249 (75.5%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Female </td>
                     <td>24 (35.3%)</td>
                     <td>80 (24.3%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Tumor diameter </td>
                     <td> </td>
                     <td> </td>
                     <td>8.867</td>
                     <td>0.003</td>
                  </tr>
                  <tr>
                     <td> ≤5 cm</td>
                     <td>28 (41.2%)</td>
                     <td>200 (60.8%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> &gt;5 cm</td>
                     <td>40 (58.8%)</td>
                     <td>129 (39.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Tumor location</td>
                     <td> </td>
                     <td> </td>
                     <td>1.470</td>
                     <td>0.479</td>
                  </tr>
                  <tr>
                     <td> Upper 1/3</td>
                     <td>25 (36.8%)</td>
                     <td>132 (40.1%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Middle 1/3</td>
                     <td>7 (10.3%)</td>
                     <td>47 (14.3%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Lower 1/3</td>
                     <td>36 (52.9%)</td>
                     <td>150 (45.6%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Borrmann type</td>
                     <td> </td>
                     <td> </td>
                     <td>7.399</td>
                     <td>0.060</td>
                  </tr>
                  <tr>
                     <td> Borrmann I</td>
                     <td>8 (11.8%)</td>
                     <td>30 (9.1%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Borrmann II</td>
                     <td>12 (17.6%)</td>
                     <td>113 (34.3%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Borrmann III</td>
                     <td>41 (60.3%)</td>
                     <td>162 (49.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Borrmann IV</td>
                     <td>7 (10.3%)</td>
                     <td>24 (7.3%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Depth of invasion</td>
                     <td> </td>
                     <td> </td>
                     <td>22.274</td>
                     <td>&lt;0.001</td>
                  </tr>
                  <tr>
                     <td> T
                        <sub>1</sub>
                     </td>
                     <td>2 (2.9%)</td>
                     <td>60 (18.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> T
                        <sub>2</sub>
                     </td>
                     <td>7 (10.3%)</td>
                     <td>77 (23.4%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> T
                        <sub>3</sub>
                     </td>
                     <td>33 (48.5%)</td>
                     <td>125 (38.0%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> T
                        <sub>4</sub>
                     </td>
                     <td>26 (38.2%)</td>
                     <td>67 (20.4%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Lymph node metastasis</td>
                     <td> </td>
                     <td> </td>
                     <td>10.130</td>
                     <td>0.017</td>
                  </tr>
                  <tr>
                     <td> N
                        <sub>0</sub>
                     </td>
                     <td>13 (19.1%)</td>
                     <td>121 (36.8%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> N
                        <sub>1</sub>
                     </td>
                     <td>15 (22.1%)</td>
                     <td>76 (23.1%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> N
                        <sub>2</sub>
                     </td>
                     <td>23 (33.8%)</td>
                     <td>82 (24.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> N
                        <sub>3</sub>
                     </td>
                     <td>17 (25.0%)</td>
                     <td>50 (15.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>TNM stage </td>
                     <td> </td>
                     <td> </td>
                     <td>10.827</td>
                     <td>0.013</td>
                  </tr>
                  <tr>
                     <td> I</td>
                     <td>6 (8.8%)</td>
                     <td>82 (24.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> II</td>
                     <td>11 (16.2%)</td>
                     <td>58 (17.6%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> III</td>
                     <td>28 (41.2%)</td>
                     <td>119 (36.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> IV</td>
                     <td>23 (33.8%)</td>
                     <td>70 (21.3%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Peritoneal dissemination</td>
                     <td> </td>
                     <td> </td>
                     <td>11.849</td>
                     <td>0.001</td>
                  </tr>
                  <tr>
                     <td> P (+)</td>
                     <td>20 (29.4%)</td>
                     <td>42 (12.8%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> P (−)</td>
                     <td>48 (70.6%)</td>
                     <td>287 (87.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Hepatic metastasis</td>
                     <td> </td>
                     <td> </td>
                     <td>0.386</td>
                     <td>0.535</td>
                  </tr>
                  <tr>
                     <td> H (+)</td>
                     <td>3 (4.4%)</td>
                     <td>21 (6.4%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> H (−)</td>
                     <td>65 (95.6%)</td>
                     <td>308 (93.6%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Curability</td>
                     <td> </td>
                     <td> </td>
                     <td>6.440</td>
                     <td>0.011</td>
                  </tr>
                  <tr>
                     <td> Curative</td>
                     <td>43 (63.2%)</td>
                     <td>256 (77.8%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Noncurative</td>
                     <td>25 (36.8%)</td>
                     <td>73 (22.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
               </tbody>
            </table>
         </div>
         <div id="tab2">
            <label>Table 2</label>
            <caption>
               <p>Comparison of clinicopathological features between MC and PDC patients for gastric
                  cancer.
               </p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th> </th>
                     <th>MC (68 cases)</th>
                     <th>PDC (599 cases)</th>
                     <th>
                        <i>χ</i>
                        <sup>2</sup> value
                     </th>
                     <th>
                        <i>P</i> value
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Age </td>
                     <td> </td>
                     <td> </td>
                     <td>4.936</td>
                     <td>0.026</td>
                  </tr>
                  <tr>
                     <td> ≤60 years</td>
                     <td>34 (50.0%)</td>
                     <td>382 (63.8%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> &gt;60 years</td>
                     <td>34 (50.0%)</td>
                     <td>217 (36.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Gender </td>
                     <td> </td>
                     <td> </td>
                     <td>0.032</td>
                     <td>0.858</td>
                  </tr>
                  <tr>
                     <td> Male </td>
                     <td>44 (64.7%)</td>
                     <td>381 (63.6%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Female </td>
                     <td>24 (35.3%)</td>
                     <td>218 (36.4%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Tumor diameter </td>
                     <td> </td>
                     <td> </td>
                     <td>2.318</td>
                     <td>0.128</td>
                  </tr>
                  <tr>
                     <td> ≤5 cm</td>
                     <td>28 (41.2%)</td>
                     <td>305 (50.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> &gt;5 cm</td>
                     <td>40 (58.8%)</td>
                     <td>294 (49.1%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Tumor location</td>
                     <td> </td>
                     <td> </td>
                     <td>3.271</td>
                     <td>0.195</td>
                  </tr>
                  <tr>
                     <td> Upper 1/3</td>
                     <td>25 (36.8%)</td>
                     <td>185 (30.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Middle 1/3</td>
                     <td>7 (10.3%)</td>
                     <td>115 (19.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Lower 1/3</td>
                     <td>36 (52.9%)</td>
                     <td>299 (49.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Borrmann type</td>
                     <td> </td>
                     <td> </td>
                     <td>5.997</td>
                     <td>0.112</td>
                  </tr>
                  <tr>
                     <td> Borrmann I</td>
                     <td>8 (11.8%)</td>
                     <td>52 (8.7%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Borrmann II</td>
                     <td>12 (17.6%)</td>
                     <td>191 (31.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Borrmann III</td>
                     <td>41 (60.3%)</td>
                     <td>301 (50.3%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Borrmann IV</td>
                     <td>7 (10.3%)</td>
                     <td>55 (9.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Depth of invasion</td>
                     <td> </td>
                     <td> </td>
                     <td>7.864</td>
                     <td>0.049</td>
                  </tr>
                  <tr>
                     <td> T
                        <sub>1</sub>
                     </td>
                     <td>2 (2.9%)</td>
                     <td>59 (9.8%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> T
                        <sub>2</sub>
                     </td>
                     <td>7 (10.3%)</td>
                     <td>101 (16.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> T
                        <sub>3</sub>
                     </td>
                     <td>33 (48.5%)</td>
                     <td>280 (46.7%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> T
                        <sub>4</sub>
                     </td>
                     <td>26 (38.2%)</td>
                     <td>159 (26.5%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Lymph node metastasis</td>
                     <td> </td>
                     <td> </td>
                     <td>5.435</td>
                     <td>0.143</td>
                  </tr>
                  <tr>
                     <td> N
                        <sub>0</sub>
                     </td>
                     <td>13 (19.1%)</td>
                     <td>161 (26.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> N
                        <sub>1</sub>
                     </td>
                     <td>15 (22.1%)</td>
                     <td>172 (28.7%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> N
                        <sub>2</sub>
                     </td>
                     <td>23 (33.8%)</td>
                     <td>142 (23.7%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> N
                        <sub>3</sub>
                     </td>
                     <td>17 (25.0%)</td>
                     <td>124 (20.7%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>TNM stage </td>
                     <td> </td>
                     <td> </td>
                     <td>3.514</td>
                     <td>0.319</td>
                  </tr>
                  <tr>
                     <td> I</td>
                     <td>6 (8.8%)</td>
                     <td>95 (15.8%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> II</td>
                     <td>11 (16.2%)</td>
                     <td>115 (19.2%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> III</td>
                     <td>28 (41.2%)</td>
                     <td>228 (38.1%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> IV</td>
                     <td>23 (33.8%)</td>
                     <td>161 (26.9%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Peritoneal dissemination</td>
                     <td> </td>
                     <td> </td>
                     <td>5.858</td>
                     <td>0.016</td>
                  </tr>
                  <tr>
                     <td> P (+)</td>
                     <td>20 (29.4%)</td>
                     <td>104 (17.4%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> P (−)</td>
                     <td>48 (70.6%)</td>
                     <td>495 (82.6%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Hepatic metastasis</td>
                     <td> </td>
                     <td> </td>
                     <td>0.001</td>
                     <td>0.971</td>
                  </tr>
                  <tr>
                     <td> H (+)</td>
                     <td>3 (4.4%)</td>
                     <td>27 (4.5%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> H (−)</td>
                     <td>65 (95.6%)</td>
                     <td>572 (95.5%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Curability</td>
                     <td> </td>
                     <td> </td>
                     <td>1.433</td>
                     <td>0.231</td>
                  </tr>
                  <tr>
                     <td> Curative</td>
                     <td>43 (63.2%)</td>
                     <td>421 (70.3%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> Noncurative</td>
                     <td>25 (36.8%)</td>
                     <td>178 (29.7%)</td>
                     <td> </td>
                     <td> </td>
                  </tr>
               </tbody>
            </table>
         </div>
         <div id="tab3">
            <label>Table 3</label>
            <caption>
               <p>Survival comparisons between MC and WMDC patients for gastric cancer.</p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th> </th>
                     <th>WMDC</th>
                     <th>MC</th>
                     <th>
                        <i>χ</i>
                        <sup>2</sup>
                        value
                     </th>
                     <th>
                        <i>P</i> value
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Total</td>
                     <td> </td>
                     <td> </td>
                     <td>12.61</td>
                     <td>0.004</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>83.4%</td>
                     <td>64.3%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>60.5%</td>
                     <td>37.1%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>50.9%</td>
                     <td>29.4%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Early stage</td>
                     <td> </td>
                     <td> </td>
                     <td>0.676</td>
                     <td>0.411</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>100.0%</td>
                     <td>100.0%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>95.5%</td>
                     <td>100.0%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>92.5%</td>
                     <td>100.0%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Advanced stage</td>
                     <td> </td>
                     <td> </td>
                     <td>5.741</td>
                     <td>0.017</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>79.8%</td>
                     <td>63.2%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>52.3%</td>
                     <td>34.8%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>41.6%</td>
                     <td>26.5%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn>
                  <p>OS: overall survival.</p>
               </fn>
            </table-wrap-foot>
         </div>
         <div id="tab4">
            <label>Table 4</label>
            <caption>
               <p>Survival comparisons between MC and PDC patients for gastric cancer.</p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th> </th>
                     <th>PDC</th>
                     <th>MC</th>
                     <th>
                        <i>χ</i>
                        <sup>2</sup> value
                     </th>
                     <th>
                        <i>P</i> value
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Total</td>
                     <td> </td>
                     <td> </td>
                     <td>2.020</td>
                     <td>0.155</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>72.2%</td>
                     <td>64.3%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>47.9%</td>
                     <td>37.1%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>38.4%</td>
                     <td>29.4%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Early stage</td>
                     <td> </td>
                     <td> </td>
                     <td>0.402</td>
                     <td>0.526</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>100.0%</td>
                     <td>100.0%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>89.5%</td>
                     <td>100.0%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>85.0%</td>
                     <td>100.0%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Advanced stage</td>
                     <td> </td>
                     <td> </td>
                     <td>0.837</td>
                     <td>0.360</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>69.2%</td>
                     <td>63.2%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>43.6%</td>
                     <td>34.8%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>33.7%</td>
                     <td>26.5%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn>
                  <p>OS: overall survival.</p>
               </fn>
            </table-wrap-foot>
         </div>
         <div id="tab5">
            <label>Table 5</label>
            <caption>
               <p>Significant subgroup survival comparisons between MGC and PDC patients.</p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th> </th>
                     <th>MGC</th>
                     <th>PDC</th>
                     <th>
                        <i>χ</i>
                        <sup>2</sup> value
                     </th>
                     <th>
                        <i>P</i> value
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Age ≤ 60 years</td>
                     <td> </td>
                     <td> </td>
                     <td>3.968</td>
                     <td>0.046</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>64.7%</td>
                     <td>75.2%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>34.7%</td>
                     <td>51.6%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>26.0%</td>
                     <td>40.7%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Tumor diameter ≤ 5 cm</td>
                     <td> </td>
                     <td> </td>
                     <td>4.796</td>
                     <td>0.029</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>60.7%</td>
                     <td>85.9%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>45.5%</td>
                     <td>68.3%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>40.5%</td>
                     <td>56.6%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Borrmann III type</td>
                     <td> </td>
                     <td> </td>
                     <td>5.152</td>
                     <td>0.023</td>
                  </tr>
                  <tr>
                     <td> 1-year OS rate</td>
                     <td>55.3%</td>
                     <td>70.8%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 3-year OS rate</td>
                     <td>30.5%</td>
                     <td>46.4%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td> 5-year OS rate</td>
                     <td>22.8%</td>
                     <td>36.6%</td>
                     <td> </td>
                     <td> </td>
                  </tr>
               </tbody>
            </table>
         </div>
         <div id="tab6">
            <label>Table 6</label>
            <caption>
               <p>Cox regression analysis results for gastric cancer.</p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th>Factors </th>
                     <th>Univariate regression analysis</th>
                     <th>Multivariate regression analysis </th>
                  </tr>
                  <tr>
                     <th>RR</th>
                     <th>95% CI</th>
                     <th>
                        <i>P</i> value
                     </th>
                     <th>RR</th>
                     <th>95% CI</th>
                     <th>
                        <i>P</i> value
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Elder age</td>
                     <td>1.222</td>
                     <td>1.022–1.461</td>
                     <td>0.028</td>
                     <td>1.341</td>
                     <td>1.118–1.610</td>
                     <td>0.002</td>
                  </tr>
                  <tr>
                     <td>Gender</td>
                     <td>0.689</td>
                     <td>—</td>
                     <td>0.407</td>
                     <td> </td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Tumor diameter</td>
                     <td>2.999</td>
                     <td>2.487–3.616</td>
                     <td>&lt;0.001</td>
                     <td>1.560</td>
                     <td>1.283–1.896</td>
                     <td>&lt;0.001</td>
                  </tr>
                  <tr>
                     <td>Histological type</td>
                     <td>1.144</td>
                     <td>1.051–1.246</td>
                     <td>0.002</td>
                     <td> </td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Tumor location</td>
                     <td>0.199</td>
                     <td>—</td>
                     <td>0.655</td>
                     <td> </td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Borrmann type</td>
                     <td>2.068</td>
                     <td>1.814–2.358</td>
                     <td>&lt;0.001</td>
                     <td> </td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Depth of invasion</td>
                     <td>2.891</td>
                     <td>2.519–3.318</td>
                     <td>&lt;0.001</td>
                     <td> </td>
                     <td> </td>
                     <td> </td>
                  </tr>
                  <tr>
                     <td>Lymph nodes metastasis</td>
                     <td>2.899</td>
                     <td>2.535–3.316</td>
                     <td>&lt;0.001</td>
                     <td>1.719</td>
                     <td>1.447–2.041</td>
                     <td>&lt;0.001</td>
                  </tr>
                  <tr>
                     <td>TNM stage</td>
                     <td>1.986</td>
                     <td>1.851–2.130</td>
                     <td>&lt;0.001</td>
                     <td>1.374</td>
                     <td>1.242–1.520</td>
                     <td>&lt;0.001</td>
                  </tr>
                  <tr>
                     <td>Adjuvant chemotherapy</td>
                     <td>0.740</td>
                     <td>0.601–0.910</td>
                     <td>0.004</td>
                     <td>0.752</td>
                     <td>0.607–0.931</td>
                     <td>0.009</td>
                  </tr>
                  <tr>
                     <td>Radical resection</td>
                     <td>6.705</td>
                     <td>5.530–8.129</td>
                     <td>&lt;0.001</td>
                     <td>2.453</td>
                     <td>1.945–3.095</td>
                     <td>&lt;0.001</td>
                  </tr>
               </tbody>
            </table>
         </div>
      </div>
   </article>
</html>